Introduction/Background*Olaparib and niraparib are poly ADP-ribose polymerase inhibitors (PARPis) that have shown efficacy as maintenance treatment in platinum-sensitive relapsed ovarian cancer (PSROC). The aim of this study was to assess the effectiveness and safety of maintenance PARPis in patients with PSROC, in a comprehensive cancer centre.
Methodology We retrospectively evaluated patients with PSROC treated with maintenance olaparib (400mg bid, capsules or 300mg bid, tablets) and niraparib (300mg id), who received ≥2 previous lines of platinum-based chemotherapy (ChT) and had a partial or complete response to the last platinum-based regimen. Patients who received olaparib were BRCA 1/2 mutated (germline and/or somatic) and those who received niraparib were BRCA 1/2 wild-type. Study endpoints were progression-free survival (PFS), overall survival (OS) and adverse events (AEs).
Result(s)*Between May 2016 and December 2020, 35 patients received maintenance PARPis (21 received olaparib and 14 received niraparib). Median age was 55 years (43-75), and all had ECOG ≤1. The majority had an ovary primary tumour location (74.3%) with serous histology (85.7%). Most patients (65.7%) received 2 prior platinum regimens; 22 (62.9%) had partial response and 13 (37.1%) had complete response to last platinum-based ChT. Median follow-up was 15.1 months (1.8-60.1), with 26 patients alive (61.9% olaparib and 92.8% niraparib patients alive). Median PFS was 7.0 months (95%CI 4.3-9.7) [median PFS for BRCA 1/2 mutated and BRCA 1/2 wild-type patients was 8.3 (95%CI 6.0-10.6) and 5.9 (95%CI 2.3-9.4) months, respectively]. There were no differences in PFS by number of prior platinum regimens, response to last platinum-based ChT or time-to-progression after penultimate platinum-based ChT (>6-12 vs >12 months). Median OS was not reached. Grade ≥3 AEs (anaemia, thrombocytopaenia, neutropaenia and nausea) occurred in 11 (31.4%) patients (17.1% with olaparib and 14.3% with niraparib). Treatment was suspended in 24 (68.6%) patients: 20 (57.2%) due to progression (34.3% with olaparib and 22.9% with niraparib) and 3 (8.6%) due to toxicity to niraparib (none due to olaparib). Eighteen (51.4%) patients required dose reduction due to AEs (28.6% with olaparib and 22.8% with niraparib).
Conclusion*Maintenance PARPis in real-world setting is effective and has a safe toxicity profile.
Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.